D-0551-2023 Class II Ongoing

Recalled by Northwind Pharmaceuticals LLC — Indianapolis, IN

FDA drug recall D-0551-2023 was initiated by Northwind Pharmaceuticals LLC on Mar 16, 2023 and is designated Class II. Reason for recall: CGMP Deviations The recall status is ongoing. Affected quantity: a) 230 bottles; b) 22 bottles.

Recall details

Product Type
Drugs
Report Date
May 3, 2023
Initiation Date
Mar 16, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
a) 230 bottles; b) 22 bottles

Product description

Glimepiride Tablets, USP 2mg, packaged in a) 30-count bottles (NDC 51655-383-52), and b)90-count bottles (NDC 51655-383-26), Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46203.

Reason for recall

CGMP Deviations

Distribution pattern

Nationwide with the United States

Code information

a) Lot #: F106252201, Exp. Date 09/30/2024; F106252301, F106252303, Exp. Date 5/31/2025; F106252304, Exp. Date 07/31/2025 b) Lot #: F106252302, Exp. Date 07/31/2025

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0551-2023
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0551-2023. Report a data issue: hello@regdatalab.com.